Research programme: analgesics - Vernalis/Xenome

Drug Profile

Research programme: analgesics - Vernalis/Xenome

Alternative Names: Analgesics research programme - Vernalis/Xenome

Latest Information Update: 09 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vernalis; Xenome
  • Class
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 26 Jul 2005 Ionix Pharmaceuticals has been acquired and merged into Vernalis
  • 05 Apr 2004 This programme is still in active development
  • 11 Jul 2002 Preclinical trials in Pain in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top